Home

The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).

SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.


Visitors and news

News: Evaluation of new HPV vaccine by IARC and partners supports recommendation to grant marketing authorization for the vaccine

05/07/2022
Scientists from the International Agency for Research on Cancer (IARC) were part of a unique collaboration between the Department of Biotechnology of the Government of India, the United States National Institutes of Health, and the Bill & Melinda Gates Foundation to support the evaluation of a quadrivalent human papillomavirus (HPV) vaccine manufactured by the Serum Institute of India (SII) in females and males aged 9–26 years. This unique model of public–private partnership resulted in a successful and timely completion of phase II and phase III vaccine efficacy trials, despite the threat posed by the COVID-19 pandemic. On 15 June 2022, after reviewing the study outcomes, the Subject Expert Committee (SEC) on Vaccines to advise the Drugs Controller General of India recommended granting marketing authorization for the new vaccine for females and males aged 9–26 years.
Read the IARC news.

New release (June) of the CanScreen5 platform with new country data

01/07/2022
The CanScreen5 IARC Secretariat, following support of country collaborators and validation by our scientific committee, is happy to announce the availability on the CanScreen5 platform of the following country factsheets: Bahamas, Cuba, Dominican Republic, Guyana, and Zambia.
Visit the CanScreen5 website to explore characteristics and performance of cancer screening programmes across the globe in more than 76 countries.

New publication: Effectiveness of artificial intelligence-assisted decision-making to improve vulnerable women's participation in cervical cancer screening in France: a cluster randomized controlled trial (AppDate-You)

03/06/2022
This new article describes the protocol AppDate-You of a two-arm cluster randomized controlled trial to be conducted in the Occitanie region, France. The objective of the study is to evaluate the effectiveness of a chatbot-based decision aid to improve vulnerable women's participation in the HPVss detection-based CCS care pathwayin the HPVss detection-based CCS care pathway. This study is supported by The French National Cancer Institute (INCa).
View the article.

New publication: Evaluation of effectiveness, acceptability, and safety of thermal ablation in the treatment of cervical neoplasia in Burundi

23/05/2022
Cervical cancer remains a major public health issue in resource-constrained settings. Appropriate management of precancer lesions is a key strategy to achieve cervical cancer elimination. Many low-income countries provide cryotherapy as ablative treatment while thermal ablation (TA) is a more practical and sustainable alternative, although more evidence is needed. This article published in IJC, reports the efficacy of thermal ablation based on the cure rate at 12 months and its potential use in the context of the “screen-and-treat” approach in Burundi.
View the article.

CBIG-SCREEN project: field visit to Estonia

16-05-2022 – 19-05-2022
Estonia is the second country visited within the CBIG-SCREEN project to assess the capacity of cervical cancer screening related services. Drs Isabel Mosquera and Keitly Mensah travelled to screening, and colposcopy and treatment facilities in Tallinn and the county of Ida-Viru. This capacity assessment is key to develop the intervention in a later phase of the project.

All visitors and news


Scientific papers

Selmouni F., Guy M., Muwonge R., Nassiri A., Lucas E., Basu P., Sauvaget C. Effectiveness of artificial intelligence-assisted decision-making to improve vulnerable women's participation in cervical cancer screening in France: a cluster randomized controlled trial (AppDate-You). JMIR Res Protoc. 2022 Jun 3
PMID: 35771872
Zhang L., Sauvaget C., Mosquera I., Basu P. Efficacy, acceptability and safety of ablative versus excisional procedure in the treatment of histologically confirmed CIN2/3: A systematic review. BJOG. 2022 Jun 11.
PMID: 35689493
Sauvaget C., Bazikamwe S., Lucas E., Ndayikengurukiye A., Harerimana S., Barango P. Evaluation of effectiveness, acceptability, and safety of thermal ablation in the treatment of cervical neoplasia in Burundi. Int J Cancer. 2022 May 14.
PMID: 35567576

All scientific papers

IARC, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France - Tel: +33 (0)4 72 73 84 85 - Fax: +33 (0)4 72 73 85 75
© IARC 2022 - Terms of use  -  Privacy Policy.